Sudeep Pharma Shares Fall 6%

Sudeep Pharma's newly-listed shares dropped more than 6 percent to their day's low on December 22, following the release of the company's Q2 results for the ongoing financial year 2026.

Q2 Results Overview

The company reported a consolidated net profit of Rs 45.74 crore for the July-September quarter of FY26, marking a fall of more than 6 percent year-on-year (YoY) from the Rs 48.75 crore net profit reported in the same period of the previous financial year.

Financial Performance

The firm's revenue from operations rose over 9 percent YoY to Rs 162.67 crore in Q2 FY26, from Rs 148.80 crore in Q2 FY25. However, expenses grew more than 27 percent to Rs 113.30 crore during the quarter under review, resulting in a contracted EBITDA margin of 38 percent from 43.4 percent a year ago.

Management's Outlook

Sudeep Pharma Managing Director Sujit Bhayani stated, "The increasing global focus on health and wellness continues to drive demand for nutritional supplements, reflecting a broader shift towards preventive healthcare. Supported by an expanding customer base and a growing product portfolio, we remain confident in our ability to deliver long-term, sustainable growth for all stakeholders."

Stock Performance

Sudeep Pharma shares made a strong stock market debut on November 28, listing at Rs 730 apiece on NSE, marking a premium of more than 23 percent over the IPO price of Rs 593 apiece. The stock has so far fallen nearly 12 percent from its listing price but is still up nearly 9 percent from its IPO price.

Remember, this is perspective, not prediction. Do your own research before making any investment decisions.